Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TKNO 
Alpha Teknova Inc (TKNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: TKNO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10
1 Year Target Price $10
| 3 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.17% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 211.92M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 5 | Beta 0.32 | 52 Weeks Range 3.94 - 10.37 | Updated Date 09/11/2025 |
52 Weeks Range 3.94 - 10.37 | Updated Date 09/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -55.24% | Operating Margin (TTM) -32.92% |
Management Effectiveness
Return on Assets (TTM) -11.8% | Return on Equity (TTM) -27.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 216890061 | Price to Sales(TTM) 5.44 |
Enterprise Value 216890061 | Price to Sales(TTM) 5.44 | ||
Enterprise Value to Revenue 5.57 | Enterprise Value to EBITDA -6.23 | Shares Outstanding 53515200 | Shares Floating 10346622 |
Shares Outstanding 53515200 | Shares Floating 10346622 | ||
Percent Insiders 10.82 | Percent Institutions 85.26 |
Upturn AI SWOT
Alpha Teknova Inc
Company Overview
History and Background
Alpha Teknova, Inc. was founded in 1975. Initially focused on custom media formulations, it has evolved into a leading provider of critical reagents and solutions for genomics, cell biology, and bioproduction.
Core Business Areas
- Genomics: Offers reagents and kits for DNA/RNA extraction, amplification, and sequencing.
- Cell Biology: Provides cell culture media, sera, supplements, and reagents for cell-based assays and research.
- Bioproduction: Supplies buffers, chemicals, and custom solutions for biopharmaceutical manufacturing.
Leadership and Structure
Todd Dawson serves as the CEO. The company operates with a functional organizational structure, encompassing R&D, manufacturing, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Market Share: Alpha Teknova does not have a dominant position but holds a niche market share amongst others that are larger competitors.
- Product Name 1: Cell Culture Media: Wide range of media formulations for various cell types. Revenue data not publicly available. Competitors include Thermo Fisher Scientific (TMO), Merck KGaA (MRK), and Cytiva.
- Market Share: Alpha Teknova does not have a dominant position but holds a niche market share amongst others that are larger competitors.
- Product Name 2: Custom Buffers and Solutions: Tailored buffer solutions for bioprocessing applications. Revenue data not publicly available. Competitors include Avantor (AVTR), and Cytiva.
Market Dynamics
Industry Overview
The life science reagents market is experiencing robust growth driven by advancements in genomics, cell biology, and biopharmaceutical development. High demand for personalized medicine and cell-based therapies are propelling market expansion.
Positioning
Alpha Teknova occupies a niche position, focusing on high-quality, customizable reagents and solutions. Its competitive advantage lies in its ability to provide tailored offerings and responsive customer service.
Total Addressable Market (TAM)
The total addressable market for life science reagents is estimated to be worth billions of dollars. Alpha Teknova is positioned to capture a larger share of the growing market by expanding its product portfolio and customer base.
Upturn SWOT Analysis
Strengths
- Customization capabilities
- High-quality products
- Strong customer relationships
- Agile manufacturing
- Extensive product catalog
Weaknesses
- Smaller scale compared to industry giants
- Limited brand recognition
- Dependence on specific customer segments
- Lower budget for R&D
- Sales and marketing budget is limited
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships
- Acquisition of complementary technologies
- Increased focus on bioproduction solutions
- Capturing the expanding market
Threats
- Intense competition
- Price pressures
- Regulatory changes
- Technological disruptions
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Merck KGaA (MRK)
- Avantor (AVTR)
- Cytiva (Part of Danaher Corporation (DHR))
Competitive Landscape
Alpha Teknova faces intense competition from larger, well-established companies. Its advantage lies in its specialization, customer service, and customization capabilities, allowing it to cater to niche market segments effectively.
Growth Trajectory and Initiatives
Historical Growth: Growth trends are available by analyzing financial data from previous years.
Future Projections: Analyst estimates can be found through financial analysis tools and research reports.
Recent Initiatives: Recent strategic initiatives can be found in their press releases and annual reports.
Summary
Alpha Teknova, Inc. holds a competitive position in the life science reagents market due to its customization and customer service, but must face immense competition from larger and more established companies. The current focus should be on increased market recognition and expansion of its client and product base. Future initiatives must focus on expanding the client base and capturing a larger share of the market, while being aware of supply chain disruptions and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Financial Analysis Tools
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are approximate estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Teknova Inc
Exchange NASDAQ | Headquaters Hollister, CA, United States | ||
IPO Launch date 2021-06-25 | President, CEO & Director Mr. Stephen Gunstream | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 173 | Website https://www.teknova.com |
Full time employees 173 | Website https://www.teknova.com | ||
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.